Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076970 · ClinicalTrials.gov registry record · Phase 1
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
A Phase 1 study of Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT03076970: Completed Phase 1 study of Migraine, sponsored by Eli Lilly and Company.
NCT03076970 is a Phase 1 study of Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 42 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03076970, a Phase 1 study of Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
Primary Outcome
Vital signs were measured in semi-supine position after 5 minutes rest. Serial vital signs assessed when lasmiditan is administered alone and when sumatriptan is administered alone compared to when lasmiditan and sumatriptan are administered together.
Conditions Studied
Interventions
- DRUG matching placebo
- DRUG lasmiditan 200 mg
- DRUG Sumatriptan
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2017-04-13 |
| Phase | Phase 1 |
What the finished NCT03076970 record still lists
NCT03076970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which matching placebo is the first listed.
NCT03076970 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03076970 about?
NCT03076970 is a clinical study titled "Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants". This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
What is the current status of trial NCT03076970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-03-21. Estimated completion is 2017-04-13.
What conditions does trial NCT03076970 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03076970?
The interventions under investigation include: matching placebo (DRUG), lasmiditan 200 mg (DRUG), Sumatriptan (DRUG).
Who is sponsoring clinical trial NCT03076970?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03076970 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03076970's enrollment target sits among peer trials
42 86th of 102 higher than 17 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI